Oncology

Latest News

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

By AJMC Contributor

July 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

August 11th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 11th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

October 25th 2016

How Can Practices Seek Success With Oncology Payment Reform?

Surabhi Dangi-Garimella, PhD

At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance, held October 24-25, 2016, in Tyson’s Corner, Virginia, Bruce Gould, MD, presented an overview of how cancer care has improved over the years, what the challenges are, and how practices can adapt to payment reform.

Dr Marianne Fazen on Why Cancer Is a Major Concern for Employers

October 25th 2016

Dr Marianne Fazen on Why Cancer Is a Major Concern for Employers

Employers face tough decisions about rising costs, high-quality care, coordination of benefits, and workplace accommodations when employees are diagnosed with cancer, but they will always want to support those employees as best they can, according to Marianne Fazen, PhD, president and CEO of the Texas Business Group on Health.

Dr Kashyap Patel Discusses Challenges of OCM Implementation

October 25th 2016

Dr Kashyap Patel Discusses Challenges of OCM Implementation

Adopting the Oncology Care Model (OCM) is a challenging task for oncology practices that have to redesign their practices, but the shift from volume-based to value-based care is the way of the future, said Kashyap Patel, MD, of the Carolina Blood & Cancer Center.

October 24th 2016

Prior Authorization Pilot Reduced Health Plan's Cancer Drug Costs by 20%

Surabhi Dangi-Garimella, PhD

Including a real-time decision support tool in the prior authorization process significantly reduced the cost of therapy for UnitedHealthcare, while complying with nationally accepted guidelines established by the National Comprehensive Cancer Network.

October 24th 2016

Geographical Disparities Exist With US Smoking Prevention Policies

Surabhi Dangi-Garimella, PhD

Analysis by researchers from the American Cancer Society has found that US southern states rank at the top when it comes to death from cigarette smoking.

This Week in Managed Care: October 21, 2016

October 21st 2016

This Week in Managed Care: October 21, 2016

The top stories in managed care included Vice President Joe Biden's released his report on the Cancer Moonshot initiative, complaints were filed against 7 insurers for discriminating against people with HIV, and Pfizer announced it plans to launch its Remicade biosimilar in November.

October 21st 2016

5 Approaches for Improved Collaboration in Oncology Care

Surabhi Dangi-Garimella, PhD

Communication gaps complicate healthcare and can devastate the prognosis of a patient undergoing cancer treatment. Here are a few ways to overcome inconsistencies with cancer care delivery

October 20th 2016

Obesity: A Growing Burden for Cancer Survivors

Patients with a history of cancer were more likely to suffer from obesity than the general population, according to new research studying the incidence of obesity in cancer survivors.

October 20th 2016

NCHS Report: Rising Survivorship in Pediatric Cancers, Brain Cancer Leading Cause of Death

Surabhi Dangi-Garimella, PhD

Brain cancer has replaced leukemia as the leading cause of cancer-related death in children and adolescents diagnosed with cancer.

October 20th 2016

Underutilization of Follow-up Imaging in Breast Cancer Survivors a Cause for Concern

Surabhi Dangi-Garimella, PhD

A study presented at the 2016 Annual Clinical Congress of the American College of Surgeons claims that one-third of women diagnosed with breast cancer do not receive their follow-up exam.

October 19th 2016

Study Recommends Nutritional Intervention for Survivors of Childhood Cancer

Surabhi Dangi-Garimella, PhD

Diets lacking essential nutrients can exacerbate chronic conditions in survivors of childhood cancer and dietary interventions might be necessary to reduce morbidities in this population.

October 19th 2016

Bach, Califf Elected to National Academy of Medicine

Seventy Americans and 9 international members were elected to the National Academy of Medicine this week.

October 19th 2016

First PD-L1 Inhibitor Approved as Second-Line Treatment for NSCLC

Surabhi Dangi-Garimella, PhD

Atezolizumab, an inhibitor of the programmed death ligand-1 protein, has been approved for the treatment of patients with non-small cell lung cancer who failed to respond to treatment with platinum-based chemotherapy.

October 18th 2016

Minding the Gaps and Filling the Chasms in Oncology

Joseph Alvarnas, MD

As we enter a time of extraordinary advances in cancer care, some of the optimism over these advances has been temÂpered by the growing realization of the challenges of delivering these cancer care solutions.

October 17th 2016

Vice President Biden Delivers Cancer Moonshot Report to the Nation

Surabhi Dangi-Garimella, PhD

Vice President Joe Biden today presented the Cancer Moonshot report to President Barack Obama and the nation, delineating an actionable plan to transform cancer research and care delivery.

October 17th 2016

Enhancing Healthcare Delivery Research at the National Cancer Institute

Ann M. Geiger, MPH, PhD Ashley W. Smith, PhD, MPH Sarah C. Kobrin, PhD, MPH Stephen H. Taplin, MD

The National Cancer Institute's Division of Cancer Control and Population Sciences created the Healthcare Delivery Research Program in January 2015, recognizing the need for empirical evidence to address cancer care challenges.

October 14th 2016

Breast Cancer Death Rates Drop, but Racial Disparities Linger

Christina Mattina

Data released by the CDC today indicate that while breast cancer deaths are on the decline, black women still have worse outcomes than white women. The report also noted disparate trends in breast cancer incidence among different races and age groups.

This Week in Managed Care: October 14, 2016

October 14th 2016

This Week in Managed Care: October 14, 2016

This week, the top stories in managed care included HHS releasing the final rule for the Medicare Access and CHIP Reauthorization Act, a commentary on the downside of drug coupons, and the World Health Organization called on countries to enact a soda tax.

October 12th 2016

Radiomics to Predict Response to Antiangiogenic Therapy in Glioblastoma

Surabhi Dangi-Garimella, PhD

Radiomic combines imaging and computational technologies and can identify patients with recurrent glioblastoma who may benefit from using angiogenesis inhibitors.

October 12th 2016

Compassionate Use: FDA Is on Board, but Are Drug Manufacturers?

Surabhi Dangi-Garimella, PhD

A survey by Avalere Health found that only 19% of drug makers publicly post policies about their compassionate use programs.

October 12th 2016

What We're Reading: Limiting Use of Fentanyl, the Drug Fueling the Opioid Epidemic

What we're reading, October 12, 2016: a US senator calls for a limit to prescription fentanyl; healthcare costs aren't skyrocketing, despite claims; IBM's Watson will identify cancer treatment and clinical trials for IBM employees.

October 11th 2016

Reducing the Cost of Breast Cancer Treatment by $1 Billion

Surabhi Dangi-Garimella, PhD

A retrospective study in breast cancer patients suggests that patients can lower their out-of-pocket costs by speaking with their oncologist about alternate treatments that may be equally effective and understanding the drug coverage policy of their insurance plan.

October 11th 2016

Why You Should Attend Patient-Centered Oncology Care in Baltimore

Innovation in oncology treatments has reduced the mortality rate for cancer, but it comes at a price. At the 5th Annual Patient-Centered Oncology Care, experts will discuss cost-sharing models, as well as updates in cancer care treatment, such as precision medicine and immuno-oncology.

October 10th 2016

COST: A New Tool to Measure Financial Toxicity as a PRO

Surabhi Dangi-Garimella, PhD

Researchers at the University of Chicago have developed a clinically relevant patient-centered tool that can measure a patient’s risk for financial stress.

October 10th 2016

Estimating the Social Value of G-CSF Therapies in the United States

Jacqueline Vanderpuye-Orgle, PhD Alison Sexton Ward, PhD Caroline Huber, MPH Chelsey Kamson, BS Anupam B. Jena, MD, PhD

Granulocyte-colony stimulating factors (G-CSFs) reduce the risk of febrile neutropenia in patients with cancer. This study evaluates the clinical and nonclinical value associated with G-CSFs.

October 10th 2016

Nivolumab Disappoints, Pembrolizumab May Replace Chemotherapy in Advanced NSCLC

Surabhi Dangi-Garimella, PhD

While nivolumab failed to surpass the outcomes of chemotherapy as first-line treatment in programmed death ligand-1—expressing patients with non-small cell lung cancer (NSCLC), pembrolizumab bettered chemotherapy in improving survival in a similar cohort.

October 7th 2016

Tamoxifen and AI Can Reduce Long-Term Risk of Contralateral Breast Cancer

Surabhi Dangi-Garimella, PhD

A retrospective analysis has found that longer term adjuvant treatment with tamoxifen significantly decreases the risk of contralateral breast cancer.

This Week in Managed Care: October 7, 2016

October 7th 2016

This Week in Managed Care: October 7, 2016

This week, the top managed care stories included conference coverage from the Academy of Managed Care Pharmacy's 2016 Nexus, Bill Clinton courted controversy when discussing the Affordable Care Act, and research finds fear of a job loss can increase the risk of diabetes.

October 7th 2016

Will HHS Have the Assurance of a Patient Identifier?

Surabhi Dangi-Garimella, PhD

HHS has been banned from using a patient identifier but several organizations, including national payers, providers, and prescription drug networks, want this reversed.

October 6th 2016

State-Level Insurance Reform Improved Access for Patients With CRC in Massachusetts

Surabhi Dangi-Garimella, PhD

A study published in the Journal of Clinical Oncology found an increased rate of resection and a reduction in the probability of emergent resection for colorectal cancer (CRC) as a result of insurance expansion in Massachusetts.

...

91 92 93 94 95 96 97 98 99

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions